{"entity":{"id":"nct07381777","kind":"trial","name":"XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)","aka":["IMMUNOSTAR"],"tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin) and dostarlimab in colorectal cancer, run by Gruppo Oncologico Italiano di Ricerca Clinica, not yet recruiting.","summary":"XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients is a phase 2, randomised interventional study registered as NCT07381777 by Gruppo Oncologico Italiano di Ricerca Clinica, with a registry enrolment figure of 270 participants, started 2026-01-31 and due to reach its primary completion in 2028-07-01. Interventions recorded: XELOX (Capecitabine and Oxaliplatin); Dostarlimab. Conditions listed: Locally Advanced Rectal Cancer (LARC). Primary outcome: Clinical complete response (cCR) at 12 months. Colorectal eligibility wording from the registry: \"* Histologically proven rectal adenocarcinoma with distal extension less 16 cm from the anal verge\". Sites: Italy. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07381777","url":"https://clinicaltrials.gov/study/NCT07381777"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["capox","dostarlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07381777","phase":"2","setting":"Phase II Randomized Trial of XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients - IMMUNOSTAR Trial GOIRC-02-2024","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","enrolled":270,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07381777/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}